This article discusses how the marketing of controversial drugs in developing countries demonstrates the power and priorities of the pharmaceutical industry. Example highlighted: Estrogen-Progesterone combination drugs.
This article discusses the current state of midwifery in Canada. Seeks to make space for the discussion of the state of midwifery in order to be pro active. Reviews what is happening with midwifery in each province and discusses how to move forward.
Promotes healthy living, working, and recreational environments by identifying and assessing health risks to Canadians posed by environmental factors. Develops national risk management strategies around radiation protection, environmental contaminants, and water quality and health. Websites describes programs and provides access to publications.
British Columbia Centre of Excellence for Women's Health
Canadian Women's Health Network
Demonstrates that there are currently no mechanisms in Canada to track the health outcomes from plastic surgery, including breast implant surgery. Makes the argument for a federal registry.
Examines the delivery of new reproductive technologies and finds that there is an urgent need for well-defined boundaries around their use, and that within those boundaries, accountable regulation is needed to protect the interests of those involved.
Explains how the push to streamline the drug approval process in the world's three largest pharmaceutical markets is neglecting the special needs of women.
Presents the recommendations of the Office of Natural Health Products Transition Team on the administrative and regulatory framework for the regulation of natural health products.
Reports on the open consultation meetings on the proposed regulatory system that will provide for natural health product labelling and licensing, site licensing, good manufacturing practices, and reporting on adverse events, as well as on a proposed approach for regulating vitamins and minerals.
